Search

A 40-year-old woman developed psychosis while being treated with amantadine for Wilson's disease. The woman experienced delusions and irritability, leading to hospitalization. After reducing and stopping the dose of amantadine, along with continued treatment with other medications, she showed improvement in psychotic symptoms and was eventually discharged with a lower psychiatric rating score. [Extracted from the article]

A retrospective study of 139 patients with Wilson's disease between 2010 and 2021 found that 14 patients, aged 5.4-14.8 years, experienced treatment failure while on penicillamine or zinc therapy. Ten of these patients had poor adherence to the treatment regimen. Despite receiving zinc and penicillamine for 0.9-9.8 years, the patients exhibited elevated ALT levels, neurological issues, or acute hepatitis, indicating treatment failure. One patient died as a result of Wilson's disease. [Extracted from the article]

A 27-year-old man with worsening tremors exhibited no response to propranolol treatment. His symptoms included upper extremity tremors that extended to the lower limbs and head, worsening during voluntary movements and stress. After a neurological examination, he was diagnosed with Wilson's disease and treated with penicillamine, resulting in the complete resolution of tremors and the disease. [Extracted from the article]

A 31-year-old woman developed nephrotic syndrome while being treated with penicillamine for Wilson's disease. She had a history of Wilson's disease since the age of 15 and had previously been treated with penicillamine, trientine, and elemental zinc therapy. After experiencing worsening fatigue and elevated copper levels on zinc therapy, she was switched back to penicillamine, which led to the development of nephrotic syndrome. Once penicillamine was discontinued, her condition improved, and she was transitioned back to zinc therapy, resulting in a return to normal levels after nine months. [Extracted from the article]

A case report in the journal "Reactions Weekly" describes a patient with Wilson's disease who underwent a liver transplant and received immunosuppressant drug therapy with prednisolone, tacrolimus, and mycophenolate-mofetil. Despite the treatment, the patient experienced plasma cell rich rejection (PRCC), indicating a lack of efficacy to the drugs. The patient then received unspecified treatment, leading to stable graft function. [Extracted from the article]

This article from Reactions Weekly discusses two case reports of patients with Wilson's disease who experienced a lack of efficacy with penicillamine and trientine. The patients, a 27-year-old woman and a 20-year-old man, were initially treated with penicillamine and trientine but showed slow progression of neurological symptoms. The lack of efficacy of these medications was considered. The article does not provide specific dosages or routes of administration. [Extracted from the article]

In a retrospective study of 92 patients with Wilson's disease, eight patients experienced various toxicities during treatment with penicillamine, trientine, or zinc. These toxicities included fever, nausea, breast enlargement, vasculitis, idiopathic thrombocytopenic purpura, double vision, twisting movements of the arm, and heartburn. In some cases, discontinuation of the medication led to improvement of symptoms, while in others, treatment had to be continued due to permanent conditions. This information provides insights into potential side effects of these medications for individuals with Wilson's disease. [Extracted from the article]

A 27-year-old woman experienced a lack of efficacy while being treated with methyldopa for pregnancy-induced hypertension. The woman had a history of liver and kidney transplants, as well as respiratory failure that required a tracheostomy. She was receiving immunosuppressive therapy during her pregnancy. Despite treatment with methyldopa, her blood pressure increased and she was hospitalized. She ultimately gave birth to a baby girl via caesarean delivery. [Extracted from the article]

A retrospective study was conducted on 43 patients who underwent transplant and experienced a lack of efficacy during immunosuppressant therapy. The patients had various liver conditions and received induction immunosuppressant therapy for prophylaxis against transplant rejection. Despite multiple immunosuppressant therapies, biopsy results showed acute cellular rejection. Some patients were treated with steroids, but steroid-resistant rejection was observed in all cases. Unfortunately, two patients died, one at home and the other from cryptococcosis. [Extracted from the article]

A 60-year-old man with metastatic multiple myeloma and hyponatremia exhibited lack of efficacy during treatment with pembrolizumab, furosemide, albumin human, sodium-chloride, and sodium. He had previously undergone a liver transplantation for Wilson's disease and presented with dizziness, blurry vision, and severe hyponatremia. Despite receiving treatment, his hyponatremia did not improve. He was later diagnosed with pseudohyponatremia and acute kidney injury due to hypercholesterolemia, and three sessions of plasmapheresis resulted in improved kidney function and sodium levels. [Extracted from the article]

A 20-year-old man with Wilson's disease experienced a lack of efficacy with multiple medications, including baclofen, gabapentin, clonazepam, trihexyphenidyl, and levodopa/carbidopa, which were being used to treat his spasticity and dyskinesia. Despite receiving maximum doses of these medications, his symptoms persisted. He eventually underwent intrathecal baclofen pump implantation for further management. This case highlights the challenges in finding effective treatments for certain conditions and the need for alternative approaches in managing symptoms. [Extracted from the article]

A 37-year-old man developed hepatocellular carcinoma while being treated with penicillamine for Wilson's disease. He had been previously treated with penicillamine without any deterioration of his liver function. The patient underwent radiofrequency ablation therapy and was later diagnosed with renal cancer and recurrent hepatocellular carcinoma. The man's family history revealed that his brother also had Wilson's disease. After surgical resection of the renal cancer, the patient received hepatic arterial chemoembolization and radiofrequency ablation therapy for the hepatocellular carcinoma. The extent of potentially carcinogenic metal deposition in the affected tissue was evaluated, with copper being high in noncancerous tubules and iron being deposited in the renal cancer areas. The patient was also identified with a novel genetic mutation. [Extracted from the article]

A male child with Wilson's disease developed nephrotoxicity while being treated with penicillamine. He experienced frothy urine and proteinuria and developed nephrotic syndrome one year after starting the medication. The nephrotoxicity was believed to be caused by penicillamine, so the treatment was discontinued and zinc was given instead. The child was also treated with prednisolone, and his proteinuria resolved after four weeks. [Extracted from the article]

Author InformationAn event is serious (based on the ICH definition) when the patient outcome is:• * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important eventA 30-year-old man developed Stevens-Johnson syndrome (SJS)-toxic epidermal necrolysis (TEN) overlap during treatment with penicillamine for Wilson's disease [dosage, route and time to reaction onset not stated]. [Extracted from the article]

This document provides a list of recently published scientific literature on drug safety-related topics. The articles cover a range of subjects, including the incidence of thiazide-induced hyponatremia, the safety of SARS-CoV-2 vaccines in patients with Wilson's disease, the correlation of Esketamine with specific adverse events, the safety of therapeutic drugs for breast cancer patients, the effects of cannabis exposure on pregnancy outcomes, and the discontinuation rate and adverse events of chemoimmunotherapy for triple-negative breast cancer. [Extracted from the article]

A 28-year-old man with Wilson's disease experienced a lack of efficacy during treatment with apomorphine, botulinum-toxin-a, and penicillamine. His condition worsened, resulting in left hand spasticity and severe flexure contractures. Traditional orthosis and botulinum-toxin-a injections were unsuccessful, but an inflatable carrot orthosis showed improvement after 4 weeks. At 3 months, the patient had regained normal nail plate architecture, improved hand hygiene, reduced infection and pain, and reported improved psychological well-being. After 8 months, his overall neurological symptoms, including tremor, spasticity, and dysarthria, had improved with the use of the orthosis. [Extracted from the article]

The male patient, who developed severe hypersensitivity with a skin rash, pancytopenia and neurological deterioration secondary to penicillamine, started receiving zinc acetate, without a therapeutic response. The patients, who had WD, started receiving penicillamine [D-penicillamine; 2 patients] and zinc sulfate (1 patient). [Extracted from the article]

After receiving unspecified anti-copper treatment for 74 months, his treatment was switched to single daily dose of zinc acetate 100mg [ I route not stated i ]. B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event In a retrospective cohort study conducted between 2005 and 2020, involving 26 patients, one adult man [ I exact age at the time of reaction onset not stated i ] was described, who exhibited treatment failure with zinc acetate while being treated for Wilson's disease (WD). Maintenance therapy simplification using a single daily dose: A preliminary real-life feasibility study in patients with Wilson disease. [Extracted from the article]

His motor nerve stimulation tests of the facial nerve revealed a >10% decreasing response indicating postsynaptic neuromuscular junction disorder. B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 15-year-old boy developed myasthenia gravis during treatment with penicillamine for wilson's disease. D-penicillamine Induced Myasthenia Gravis in Wilson's Disease: A Case Report. [Extracted from the article]

Multicentre, retrospective study to assess long-term outcomes of chelator based treatment with trientine in Wilson disease patients withdrawn from therapy with d -penicillamine. However, all of them developed adverse effects in the form of iron deficiency anaemia and intestinal obstruction (n=1), exhibited elevated hepatic enzymes (n=1), acne (n=1), alopecia (n=1) or rash (n=1). B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event In a multicenter, cross-sectional retrospective study conducted between July 2015 and April 2017, five patients [ I ages and sexes not stated] i were described, who developed iron deficiency anaemia, intestinal obstruction, rash, acne, alopecia or exhibited elevated hepatic enzymes during treatment with trientine for Wilson's disease [dosage, I route and durations of treatments to reaction onsets not stated; not all outcomes stated i ]. [Extracted from the article]

Case 1: The 26-year-old woman, who had Wilson's disease, started receiving penicillamine [d-penicillamine] 300mg. She started receiving penicillamine [d-penicillamine] with dose increased to 600mg over two weeks. [Extracted from the article]

Treatment with penicillamine is associated with blood, kidney and skin adverse events (AEs) in patients with Wilson's disease (hepatolenticular degeneration), according to findings of a study published in I Clinical Drug Investigation i . "D-penicillamine treatment is associated with significant AEs mainly related to blood, kidney, and skin. Severe AEs leading to permanent treatment discontinuation occurred in 57% of patients with penicillamine intolerance, in whom the drug was not reintroduced (n=12) or was discontinued after intolerance to rechallenge (4). [Extracted from the article]